FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAgios Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGIO
Agios Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Agios Pharmaceuticals, Inc. (AGIO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAGIO
AGIO
Agios Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGIO
  1. Home
  2. Stocks
  3. Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

🇺🇸AGIO•NASDAQ

Agios Pharmaceuticals, Inc.

🇺🇸AGIO•NASDAQ
Market cap
$1.65B

Your view on AGIO

Mkt Cap
$1.65B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Agios Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Brian M. Goff
Headquarters
88 Sidney Street, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Brian M. Goff
Headquarters
88 Sidney Street, Cambridge, MA, US
Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.

The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Agios Pharmaceuticals, Inc.. Starting points for Agios Pharmaceuticals, Inc.: EPS -$6.25, beta 0.62 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Agios Pharmaceuticals, Inc.. Trailing twelve-month EPS for Agios Pharmaceuticals, Inc. stands at -$6.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Agios Pharmaceuticals, Inc.. Agios Pharmaceuticals, Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AGIO12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
TVGNTevogen Bio Holdings Inc.HealthcareNASDAQ$24.6M
TVGNWTevogen Bio Holdings Inc.HealthcareNASDAQ$5.6M
TVRDTvardi Therapeutics, Inc.HealthcareNASDAQ$13.2M
TVTXTravere Therapeutics, Inc.HealthcareNASDAQ$4.5B
TXTMProText Mobility, Inc.HealthcareOTC$15.6M
TYRATyra Biosciences, Inc.HealthcareNASDAQ$1.4B
UCBJFUCB S.A.HealthcareOTC$58.4B
UCBJYUCB S.A.HealthcareOTC$60.4B
UNCYUnicycive Therapeutics, Inc.HealthcareNASDAQ$97.8M
UPBUpstream Bio, Inc.HealthcareNASDAQ$87.2M
URGNUroGen Pharma Ltd.HealthcareNASDAQ$1.4B
USRMU.S. Stem Cell, Inc.HealthcareOTC$64,151
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Agios Pharmaceuticals, Inc., and how their positions are changing. At a $1.65B market value, institutional positions materially move Agios Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Agios Pharmaceuticals, Inc. executives and directors. Shares of Agios Pharmaceuticals, Inc. have traded between $23.42 and $62.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Agios Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Agios Pharmaceuticals, Inc.. Coverage tracks Agios Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Agios Pharmaceuticals, Inc.

AGIO AnalysisFair
Past
2
Growth
5
Health
5
Profit
1
Value
1